CBT Pharmaceuticals, Inc. is an innovative biopharmaceutical company committed to becoming a global leader in the discovery and development of oncology combination therapies by focusing on therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer. With multiple China partners, CBT strives to become a gateway to East innovation, harnessing ongoing research and resources in China to develop more affordable medicines for the rest of the world.
The company’s existing pipeline consists of five development-stage assets. CBT has three novel humanized monoclonal antibodies – CBT-501, targeting the Programmed Death-1 (PD-1) membrane receptor of immune cells, CBT-502, a Programmed Death Ligand-1 (PD-L1) that restores the body’s immune system to recognize and kill cancer cells; and CBT-509, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) molecule that blocks the interaction of CTLA-4 with its ligands CD80/CD86 thus allowing the cytotoxic T cells to function actively. In addition, CBT-10, is an oral c-MET inhibitor targeting the epithelial to mesenchymal transition (EMT) pathway and CBT-102, an oral multi-targeted kinase inhibitor that targets uncontrolled growth signaling pathways.
To be a global leader in developing novel medicines for cancer patients and improving lives.
To develop novel oncology medicines and effective combination therapies to improve the lives of those living with life-threatening malignancies.
We will pursue this mission by developing and commercializing treatment solutions as rapidly and diligently as possible for patients and the people who care for them.
We will perform our work with persistence and a sense of urgency, with integrity and scientific excellence as our guiding principles at all times.
By fostering individual performance, teamwork and the spirit of partnership, we will achieve our goal – to deliver life-saving oncolytic therapeutics to patients who suffer today.